185 related articles for article (PubMed ID: 28237207)
1. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options.
Mühlbacher AC; Sadler A
Value Health; 2017 Feb; 20(2):266-272. PubMed ID: 28237207
[TBL] [Abstract][Full Text] [Related]
2. [The Probabilistic Efficiency Frontier: A Value Assessment of Treatment Options in Hepatitis C].
Mühlbacher AC; Sadler A
Gesundheitswesen; 2019 Jan; 81(1):e21-e32. PubMed ID: 28628931
[TBL] [Abstract][Full Text] [Related]
3. Cost Recommendation under Uncertainty in IQWiG's Efficiency Frontier Framework.
Corro Ramos I; Lhachimi SK; Gerber-Grote A; Al MJ
Med Decis Making; 2017 Feb; 37(2):162-172. PubMed ID: 27005521
[TBL] [Abstract][Full Text] [Related]
4. A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG).
Gandjour A
Health Serv Manage Res; 2013 Nov; 26(4):103-9. PubMed ID: 25595007
[TBL] [Abstract][Full Text] [Related]
5. Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment.
Mühlbacher AC; Bridges JF; Bethge S; Dintsios CM; Schwalm A; Gerber-Grote A; Nübling M
Eur J Health Econ; 2017 Mar; 18(2):155-165. PubMed ID: 26846922
[TBL] [Abstract][Full Text] [Related]
6. Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers.
Stollenwerk B; Lhachimi SK; Briggs A; Fenwick E; Caro JJ; Siebert U; Danner M; Gerber-Grote A
Health Econ; 2015 Apr; 24(4):481-90. PubMed ID: 24590819
[TBL] [Abstract][Full Text] [Related]
7. Health Technology Assessment-Informed Decision Making by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care in Germany and the National Institute for Health and Care Excellence in England: The Role of Budget Impact.
Schaefer R; Hernández D; Bärnighausen T; Kolominsky-Rabas P; Schlander M
Value Health; 2023 Jul; 26(7):1032-1044. PubMed ID: 36921901
[TBL] [Abstract][Full Text] [Related]
8. The Role of Noncomparative Evidence in Health Technology Assessment Decisions.
Griffiths EA; Macaulay R; Vadlamudi NK; Uddin J; Samuels ER
Value Health; 2017 Dec; 20(10):1245-1251. PubMed ID: 29241883
[TBL] [Abstract][Full Text] [Related]
9. The efficiency frontier approach to economic evaluation of health-care interventions.
Caro JJ; Nord E; Siebert U; McGuire A; McGregor M; Henry D; de Pouvourville G; Atella V; Kolominsky-Rabas P
Health Econ; 2010 Oct; 19(10):1117-27. PubMed ID: 20575151
[TBL] [Abstract][Full Text] [Related]
10. [Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].
Krauth C; John J; Aidelsburger P; Brüggenjürgen B; Hansmeier T; Hessel F; Kohlmann T; Moock J; Rothgang H; Schweikert B; Seitz R; Wasem J;
Gesundheitswesen; 2008 Jun; 70(6):e1-16. PubMed ID: 18661452
[TBL] [Abstract][Full Text] [Related]
11. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
12. Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches.
Hagiwara Y; Shiroiwa T
Med Decis Making; 2022 Jul; 42(5):672-683. PubMed ID: 35172648
[TBL] [Abstract][Full Text] [Related]
13. Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment.
Lomas JRS
Value Health; 2019 Aug; 22(8):898-905. PubMed ID: 31426931
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
[TBL] [Abstract][Full Text] [Related]
15. A Non-inferiority Framework for Cost-Effectiveness Analysis.
Xie X; Falk L; Brophy JM; Tu HA; Guo J; Gajic-Veljanoski O; Sikich N; Dhalla IA; Ng V
Int J Technol Assess Health Care; 2019; 35(4):291-297. PubMed ID: 31337452
[TBL] [Abstract][Full Text] [Related]
16. [IQWiG's methods for the cost-benefit assessment : Comparison with an international reference scenario].
Schwalm A; Danner M; Seidl A; Volz F; Dintsios CM; Gerber A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jun; 53(6):615-22. PubMed ID: 20449550
[TBL] [Abstract][Full Text] [Related]
17. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.
Eckermann S; Willan AR
Pharmacoeconomics; 2011 Jul; 29(7):563-77. PubMed ID: 21671686
[TBL] [Abstract][Full Text] [Related]
18. The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing: combining the best of both worlds?
Sandmann FG; Mostardt S; Lhachimi SK; Gerber-Grote A
Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):475-486. PubMed ID: 29979895
[TBL] [Abstract][Full Text] [Related]
19. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
20. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
